Serum paraoxonase-3 concentration is associated with insulin sensitivity in peripheral artery disease and with inflammation in coronary artery disease

Atherosclerosis

Volumn 220, Issue 2, 2012, Pages 545-551

  Rull, Anna ^a   García, Raúl ^b   Fernández Sender, Laura ^a   García Heredia, Anabel ^a   Aragonès, Gerard ^a   Beltrán Debón, Raúl ^a   Marsillach, Judit ^c   Alegret, Josep M ^a   Martín Paredero, Vicente ^b   Mackness, Bharti ^a   Mackness, Michael ^a   Joven, Jorge ^a   Camps, Jordi ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antioxidants; Atherosclerosis; Lipoproteins; Myocardial infarction; Paraoxonases; Peripheral vascular disease

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PARAOXONASE 3; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BIOCHEMISTRY; CORONARY ARTERY DISEASE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; HAPLOTYPE; INFLAMMATION; INSULIN SENSITIVITY; MICROARRAY ANALYSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HAPLOTYPES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PHENOTYPE; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SPAIN; UP-REGULATION;

EID: 84855916509     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.11.021     Document Type: Article

References (31)

1. Seo D., Goldschmidt-Clermont P. The paraoxonase gene family and atherosclerosis. Curr Atheroscler Rep 2009, 11:182-187.
2. Primo-Parmo S.L., Sorenson R.C., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33:498-507.
3. Rodríguez-Sanabria F., Rull A., Beltrán-Debón R., et al. Tissue distribution and expression of paraoxonases and chemokines in mouse: the ubiquitous and joint localisation suggest a systemic and coordinated role. J Mol Histol 2010, 41:379-386.
4. Deakin S.P., Bioletto S., Bochaton-Piallat M.L., James R.W. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Rad Biol Med 2011, 50:102-109.
5. Ng C.J., Wadleigh D.J., Gangopadhyay A., et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001, 76:44444-44449.
6. Camps J., Marsillach J., Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009, 46:83-106.
7. Bourquard N., Shih D.M., Ng C.J., et al. The role of PON2 and PON3 in atherosclerosis and related traits. The paraoxonases: their role in disease development and xenobiotic metabolism 2008, 103-128. Springer, Dordrecht. B. Mackness, M. Mackness, M. Aviram, G. Paragh (Eds.).
8. Aragonès G., Guardiola M., Barreda M., et al. Measurement of serum paraoxonase-3 concentration: method evaluation, reference values and influence of genotypes in a population-based study. J Lipid Res 2011, 52:1055-1061.
9. Yun W.S., Rho Y.N., Park U.J., Lee K.B., Kim D.I., Kim Y.W. Prevalence of asymptomatic critical carotid artery stenosis in Korean patients with chronic atherosclerotic lower extremity ischemia: is a screening carotid duplex ultrasonography worthwhile?. J Korean Med Sci 2010, 25:1167-1170.
10. Fowkes F.G., Murray G.D., Butcher I., et al. Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008, 300:197-208.
11. Bertrán N., Camps J., Fernández-Ballart J., et al. Diet and lifestyle are associated with serum C-reactive protein concentrations in a population-based study. J Lab Clin Med 2005, 145:41-46.
12. Marsillach J., Mackness B., Mackness M., et al. Immunochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic Biol Med 2008, 45:146-157.
13. Gaidukov L., Tawfik D. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. J Lipid Res 2007, 48:1637-1646.
14. Marsillach J., Aragonès G., Beltrán R., et al. The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin Biochem 2009, 42:91-98.
15. Ferré N., Camps J., Prats E., et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002, 48:261-268.
16. Tanno K., Okamura T., Ohsawa M., et al. Comparison of low-density lipoprotein cholesterol concentrations measured by a direct homogeneous assay and by the Friedewald formula in a large community population. Clin Chim Acta 2010, 411:1774-1780.
17. Matthews D.R., Hosker J., Rudenski A., Naylor B., Treacher D., Turner R. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
18. Rull A., García R., Fernández-Sender L., et al. The role of combined assessment of defense against oxidative stress and inflammation in the evaluation of peripheral arterial disease. Curr Mol Med 2011, 11:453-464.
19. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
20. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995, 57:791-804.
21. Aviram M. Atherosclerosis: cell biology and lipoproteins - inflammation and oxidative stress in atherogenesis: protective role for paraoxonases. Curr Opin Lipidol 2011, 22:243-244.
22. Rosenblat M., Aviram M. Paraoxonases role in the prevention of cardiovascular diseases. Biofactors 2009, 35:98-104.
23. Tavori H., Vaya J., Aviram M. Paraoxonase 1 attenuates human plaque atherogenicity: relevance to the enzyme lactonase activity. Adv Exp Med Biol 2010, 660:99-111.
24. Aviram M., Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004, 37:1304-1316.
25. Brevetti M., Piscione F., Cirillo P., et al. In concomitant coronary and peripheral arterial disease, inflammation of the affected limbs predicts coronary artery endothelial dysfunction. Atherosclerosis 2008, 201:440-446.
26. Wilson A.M., Kimura E., Harada R.K., et al. Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation 2007, 116:1396-1403.
27. Draganov D.I., Stetson P.I., Watson C.E., Billecke S.S., La Du B.N. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000, 275:33435-33442.
28. Ng C.J., Bourquard N., Hama S.Y., et al. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Atheroscler Thromb Vasc Biol 2007, 27:1-7.
29. Bouman H.J., Schömig E., van Werkum J.W., et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011, 17:110-116.
30. Camps J., Joven J., Mackness B., et al. Paraoxonase-1 and clopidogrel efficacy. Nat Med 2011, 17:1041-1042.
31. Shih D.M., Xia Y.R., Wang X.P., et al. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res 2007, 100:1200-1207.